<prof_article_slide_presentation><front_label>Front Matter</front_label><above_title/><title><p>&lt;em&gt;FLT3&lt;/em&gt;-Mutated AML: Progress, Patients, and Current and Future Practice</p></title><contrbtr_pre_content><p>WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.</p></contrbtr_pre_content><contrbtr_byline><p>Harry Erba, MD, PhD</p></contrbtr_byline><contrbtr_bulk_info/><contrbtr_post_content/><supprtr_grant_group/><body_label>Body</body_label><toc_element><toc_label/><toc_type>Default</toc_type><sec_element><sec_header/><subsec_element><subsec_header/><slide_intro><div class="app-loading"><div class="webcomp-player" data-config="en/pi/editorial/studio/configs/2019/education/903975/903975_2.json" data-playertype="edu" id="cme-video-player">
                &#160;
            </div></div></slide_intro></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label><p>Abbreviations</p></toc_label><toc_type>Sidebar</toc_type><sec_element><sec_header><p>Abbreviations</p></sec_header><subsec_element><subsec_header/><slide_intro><p>AACR = American Association for Cancer Research <br/>aGvHD = acute graft vs host disease<br/>AlloSCT = allogeneic stem cell transplantation<br/>AML = acute myeloid leukemia<br/>AR = allelic ratio <br/>ASH = American Society of Hematology<br/>AZA = azacitidine<br/>CMML = chronic myelomonocytic leukemia<br/>CR = complete remission<br/>CRc = composite complete remission<br/>CRh = complete remission with partial hematologic recovery<br/>DFS = disease-free survival<br/>ED = early death<br/>EFS = event-free survival<br/>ELN = European LeukemiaNet<br/>EMA = European Medicines Agency<br/>FLAG-IDA = fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin <br/>FLT3 = FMS-like tyrosine kinase 3<br/>GI = gastrointestinal<br/>HMA = hypomethylating agent<br/>HR-MDS = high-risk myelodysplastic syndrome<br/>ITD = internal tandem duplication <br/>JM = juxtamembrane<br/>JMD = juxtamembrane domain<br/>LDAC = low-dose cytarabine<br/>M = midostaurin<br/>MDS = myelodysplastic syndrome<br/>MEC = mitoxantrone, etoposide, cytarabine<br/>ND = not determined or newly diagnosed<br/>NRM = non-relapse mortality<br/>NE = not estimable<br/>NS = not significant<br/>N/V = nausea/vomiting<br/>OS = overall survival<br/>P = placebo<br/>PD = progressive disease<br/>Pts = patients<br/>R = randomization<br/>RD = resistant disease<br/>sAML = secondary acute myeloid leukemia<br/>TKD = tyrosine kinase domain<br/>TKI = tyrosine kinase inhibitor</p></slide_intro></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label/><toc_type>References</toc_type><sec_element><sec_header/><subsec_element><subsec_header/><slide_intro><ol><li>Blau O, Berenstein R, Sindram A, Blau IW. Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia. <em>Leuk Lymphoma</em>. 2013;54:145-152. </li><li>Buchert A, Bug G, Finke J, et al. Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre Sormain trial. Presented at: 2018 American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego, CA. Abstract 661.</li><li>ClinicalTrials.gov. Quizartinib with standard of care chemotherapy and as continuation therapy in patients with newly diagnosed FLT3-ITD (+) acute myeloid leukemia (AML) (QuANTUM-First). https://clinicaltrials.gov/ct2/show/NCT02668653. Accessed July 10, 2019. </li><li>ClinicalTrials.gov. Randomized trial of gilteritinib vs midostaurin in FLT3 mutated acute myeloid leukemia. https://clinicaltrials.gov/ct2/show/NCT03836209. Accessed July 10, 2019.</li><li>ClinicalTrials.gov. Study of crenolanib vs midostaurin following induction chemotherapy and consolidation therapy in newly diagnosed FLT3 mutated AML. https://clinicaltrials.gov/ct2/show/NCT03258931. Accessed July 10, 2019.</li><li>Cooper BW, Kindwall-Keller TL, Craig MD, et al. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. <em>Clin Lymphoma Myeloma Leuk</em>. 2015;15:428-432.e2.</li><li>Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. <em>Lancet Oncol</em>. 2019;20:984-997.</li><li>Cortes JE, Khaled S, Martinelli G, et al. Efficacy and safety of single-agent quizartinib (Q), a potent and selective FLT3 inhibitor (FLT3i), in patients (pts) with FLT3-internal tandem duplication (FLT3-ITD)–mutated relapsed/refractory (R/R) acute myeloid leukemia (AML) enrolled in the global, phase 3, randomized controlled Quantum-R trial. Presented at: 2018 American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego, CA. Abstract 563.</li><li>Fröhling S, Scholl C, Levin RL, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. <em>Cancer Cell.</em> 2007;12:501-513.</li><li>Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. <em>Blood</em>. 2014;123:94-100.</li><li>Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. <em>Blood</em>. 2005;106:3658-3665.</li><li>Garcia JS, Stone RM. The development of FLT3 inhibitors in acute myeloid leukemia. <em>Hematol Oncol Clin N Am</em>. 2017;31:663-680. </li><li>HOVON. HOVON 156 AML. http://www.hovon.nl/studies/studies-per-ziektebeeld/aml.html?action=showstudie&amp;studie_id=148&amp;categorie_id=4. Accessed July 10, 2019. </li><li>Kayser S, Schlenk RF, Londono MC, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. <em>Blood</em>. 2009;114:2386-2392. </li><li>Larson RA, Mandrekar SJ, Sanford BL, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. Blood. 2017;130:145.</li><li>Lee LY, Hernandez D, Rajkhowa T, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. <em>Blood</em>. 2017;129:257-260.</li><li>Metzeler KH, Herold T, Rothenberg-Thurley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. <em>Blood</em>. 2016;128:686-696.</li><li>Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. <em>Leukemia</em>. 1996;10:1911-1918.</li><li>NEXAVAR<sup>®</sup> (sorafenib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; Approved 2015. Revised December 2018.</li><li>Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. <em>N Engl J Med</em>. 2016;374:2209-2221.</li><li>Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib significantly prolongs overall survival in patients with <em>FLT3</em>-mutated (<em>FLT3<sup>mut+</sup></em>) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase III ADMIRAL trial. Presented at the American Association for Cancer Research (AACR) 2019 annual meeting. March 29 - April 3, 2019. Atlanta, Georgia. Abstract CTPL04.</li><li>Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. <em>Blood</em>. 2013;121:4655-4662. </li><li>Reindl C, Bagrintseva K, Vempati S, et al. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. <em>Blood</em>. 2006;107:3700-3707.</li><li>Röllig C, Serve H, Hüttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <em>Lancet Oncol</em>. 2015;16:1691-1699.</li><li>Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. <em>Blood</em>. 2014;124:3441-3449.</li><li>Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with <em>FLT3</em>-ITD. <em>Blood</em>. 2019;133:840-851.</li><li>Schnittger S, Bacher U, Haferlach C, Alpermann T, Kern W, Haferlach T. Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. <em>Genes Chromosomes Cancer</em>. 2012;51:910-924.</li><li>Song Y, Magenau J, Li Y, et al. <em>FLT3 </em>mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. <em>Bone Marrow Transplant</em>. 2016;51:511-520.</li><li>Stirewalt DL, Kopecky KJ, Meshinchi S, et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. <em>Blood</em>. 2006;107:3724-3726.</li><li>Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. <em>N Engl J Med</em>. 2017;377:454-464.</li><li>Stone RM, Manley PW, Larson RA, et al. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <em>Blood Adv</em>. 2018;2:444-453. </li><li>Stone RM, Manley PW, Larson RA, et al. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <em>Blood Adv</em>. 2018;2:787.</li><li>Strati P, Kantarjian H, Ravandi F, et al. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. <em>Am J Hematol</em>. 2015;90:276-281.</li><li>Swaminathan M, Kantarjian HM, Daver N, et al. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients (pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Presented at: 2017 American Society of Hematology Annual Meeting; December 9-12, 2017; Atlanta, GA. Abstract 723.</li><li>Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. <em>Blood</em>. 2002;99:4326-4335.</li><li>Wang ES, Stone RM, Tallman MS, et al. Crenolanib, a type I FLT3 TKI, can be safely combined with cytarabine and anthracycline induction chemotherapy and results in high response rates in patients with newly diagnosed FLT3 mutant acute myeloid leukemia (AML). <em>Blood</em>. 2016;128:1071.</li><li>Williams CB, Kambhampati S, Fiskus W, et al. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. <em>Pharmacotherapy</em>. 2013;33:1341-1352.</li><li>Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. <em>Blood</em>. 2001;97:2434-2439.</li><li>XOSPATA<sup>®</sup> (gilteritinib) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc..; Approved 2018. Revised May 2019.</li><li>Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). <em>Blood</em>. 2009;114:2984-2992. </li></ol></slide_intro></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label><p>Full Live Event Audio</p></toc_label><toc_type>Sidebar</toc_type><sec_element><sec_header><p>Full Live Event Audio</p></sec_header><subsec_element><subsec_header/><slide_intro><div class="app-loading"><div class="webcomp-player" data-config="en/pi/editorial/studio/configs/2019/education/903975/903975_3.json" data-playertype="edu" id="cme-video-player">
                &#160;
            </div></div></slide_intro></subsec_element></sec_element><pg_footnotes/></toc_element><back_label>Back Matter</back_label><ref_grp><ref_item/></ref_grp><cpyrt_holder><p>WebMD Global, LLC</p></cpyrt_holder><cpyrt_ovrd/><disclmr_ovrd/><bkmtr_front><p><strong>Disclaimer</strong></p><p>The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.</p></bkmtr_front><bkmtr_glossary/><bkmtr_ack/><bkmtr_discl/><bkmtr_funding/><bkmtr_reprnt_addr/><bkmtr_abbr_notes/><bkmtr_last/><img_ttl_bkgrd/><img_publ_logo/></prof_article_slide_presentation>